A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

NCT01106508 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Recurrent or Refractory Medulloblastoma
Locally Advanced or Metastatic Basal Cell Carcinoma

Interventions

DRUG: LEQ506

Sponsor

Novartis Pharmaceuticals